David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial. We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market.

Scholar Rock shares launched 362% to 34.28. That put shares at their highest point since November 2021. The news also buoyed shares of Biohaven, which is working on a similar treatment option for ...

About Scholar Rock. Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which ...

Scholar Rock also granted the underwriters of the offering a 30-day option to purchase up to an additional 1,861,314 shares of common stock at the offering price. For perspective, ...

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...

Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock’s Board of Directors as an independent director.

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company ...

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth ...

Scholar Rock Holding focuses on the discovery of drugs for treating illnesses, in which signaling by protein growth factors is important. SRRK tested a total of 58 patients in Phase 2.